Trial Search Results
Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis
The purpose of this study is to determine whether [18F]FHBG is suitable for use as an imaging probe in cancer or rheumatoid arthritis patients enrolled in cell or gene therapy trials. In this phase 1 study we will assess the safety and biodistribution of [18F]FHBG in patients.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Sanjiv Sam Gambhir
Stanford Investigator(s):
Intervention(s):
- Radiation: [18F]FHBG
Phase:
Phase 1
Eligibility
Inclusion Criteria:
- Clinical diagnosis of brain tumor or rheumatoid arthritis
Exclusion Criteria:
- Below 18 years of age
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
ccto-office@stanford.edu
650-498-7061
Not Recruiting